Diffuse Large B-cell Lymphoma
📧 Sign up to get email alerts when something new happens for Diffuse Large B-cell Lymphoma.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-08-06EMA Authorised: Tepkinly (epcoritamab) — AbbVie Deutschland GmbH & Co. KG
EMA authorised Tepkinly (epcoritamab) for diffuse large B-cell lymphoma under conditional approval.
-
EMA approval · 2026-08-06EMA Authorised: Breyanzi (lisocabtagene maraleucel) — Bristol-Myers Squibb Pharma EEIG
The EMA has authorised Breyanzi (lisocabtagene maraleucel) for specified lymphomas, including large B-cell diffuse and follicular lymphoma, …
-
EMA approval · 2026-06-09EMA Authorised: Tepkinly (epcoritamab) — AbbVie Deutschland GmbH & Co. KG
The EMA authorised Tepkinly (epcoritamab) by AbbVie for diffuse large B-cell lymphoma, granting conditional approval.
-
EMA approval · 2026-06-08EMA Authorised: Yescarta (axicabtagene ciloleucel) — Kite Pharma EU B.V.
The EMA authorises Yescarta (axicabtagene ciloleucel) for certain lymphomas, indicating market authorization and orphan designation.
-
FDA approval · 2026-03-18FDA Approved: POLIVY — Supplemental Application (Genentech, Inc.)
The FDA approved a supplemental application for POLIVY (polatuzumab vedotin) from Genentech, expanding its labeled use.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
EMA approval · 2026-03-12EMA Authorised: Yescarta (axicabtagene ciloleucel) — Kite Pharma EU B.V.
EMA authorised Yescarta (axicabtagene ciloleucel) from Kite Pharma EU B.V. for treatment of certain B-cell lymphomas including follicular ly…
-
FDA approval · 2026-02-20FDA Approved: ZYNLONTA — Supplemental Application (ADC Therapeutics America, Inc.)
FDA overview of a supplemental application for ZYNLONTA (loncastuximab tesirine) by ADC Therapeutics America, Inc., indicating an additional…
-
EMA approval · 2026-02-06EMA Authorised: Tepkinly (epcoritamab) — AbbVie Deutschland GmbH & Co. KG
The EMA authorised Tepkinly (epcoritamab) from AbbVie Deutschland for diffuse large B-cell lymphoma, with conditional approval.
-
EMA approval · 2026-01-27EMA Authorised: Minjuvi (tafasitamab) — Incyte Biosciences Distribution B.V.
EMA authorised Minjuvi (tafasitamab) for diffuse large B-cell lymphoma with conditional approval and orphan designation.
-
FDA approval · 2026-01-16FDA Approved: ZYNLONTA — Supplemental Application (ADC Therapeutics America, Inc.)
The FDA approved a supplemental application for ZYNLONTA (loncastuximab tesirine) filed by ADC Therapeutics America, Inc., effectively updat…
-
EMA approval · 2025-12-18EMA Authorised: Breyanzi (lisocabtagene maraleucel) — Bristol-Myers Squibb Pharma EEIG
The EMA authorised Breyanzi (lisocabtagene maraleucel) for additional lymphomas, including diffuse large B-cell lymphoma and follicular lymp…
-
EMA approval · 2025-11-25EMA Authorised: Zynlonta (loncastuximab tesirine) — Swedish Orphan Biovitrum AB
The European Medicines Agency authorized Zynlonta (loncastuximab tesirine) for diffuse large B-cell lymphoma and B-cell lymphoma, under a co…
-
EMA approval · 2025-11-06EMA Authorised: Kymriah (tisagenlecleucel) — Novartis Europharm Limited
The EMA authorised Kymriah (tisagenlecleucel) for additional indications in precursor B-cell lymphoblastic leukemia/lymphoma and diffuse lar…
-
EMA approval · 2025-10-24EMA Authorised: Columvi (Glofitamab) — Roche Registration GmbH
The EMA authorised Columvi (glofitamab) from Roche Registration GmbH for diffuse large B-cell lymphoma.
-
EMA approval · 2025-10-17EMA Authorised: Polivy (polatuzumab vedotin) — Roche Registration GmbH
The European Medicines Agency authorised Polivy (polatuzumab vedotin) from Roche Registration GmbH for a B-cell lymphoma indication.
-
FDA approval · 2023-04-19FDA Approved: POLIVY — Supplemental Application (Genentech, Inc.)
FDA approved a supplemental application for POLIVY (polatuzumab vedotin) from Genentech, Inc., updating its labeling and/or approved indicat…
-
FDA approval · 2021-12-02FDA Approved: RITUXAN — Supplemental Application (Genentech, Inc.)
FDA approved a supplemental application for Rituxan (rituximab) filed by Genentech, Inc., resulting in updated labeling for the product.
-
FDA approval · 2021-06-02FDA Approved: MONJUVI — Supplemental Application (Incyte Corporation)
The FDA approved a supplemental application for MONJUVI (tafasitamab-cxix) from Incyte Corporation. The action updates the product under its…
-
FDA approval · 2021-04-23FDA Approved: ZYNLONTA — Original Application (ADC Therapeutics America, Inc.)
The FDA granted original approval for ZYNLONTA (loncastuximab tesirine) from ADC Therapeutics America, Inc. for adults with relapsed or refr…
-
FDA approval · 2020-07-31FDA Approved: MONJUVI — Original Application (Incyte Corporation)
FDA approved MONJUVI (tafasitamab-cxix) from Incyte as an original biologics license application for adult patients with relapsed or refract…
-
FDA approval · 2020-05-05FDA Approved: RITUXAN HYCELA — Supplemental Application (Genentech, Inc.)
The FDA approved a supplemental application for Rituxan HYCELA (rituximab and hyaluronidase) from Genentech, expanding its approval through …
-
FDA approval · 2019-07-23FDA Approved: RUXIENCE — Original Application (Pfizer Laboratories Div Pfizer Inc)
FDA approved Ruxience (rituximab-pvvr) from Pfizer as a biosimilar to rituximab, under an original application; the approval covers multiple…
-
FDA approval · 2019-06-10FDA Approved: POLIVY — Original Application (Genentech, Inc.)
FDA's original approval of POLIVY (polatuzumab vedotin) by Genentech for adults with relapsed or refractory diffuse large B-cell lymphoma in…
-
FDA approval · 2017-06-22FDA Approved: RITUXAN HYCELA — Original Application (Genentech, Inc.)
FDA approved RITUXAN HYCELA (rituximab and hyaluronidase) under an Original Application by Genentech. The subcutaneous formulation provides …
-
FDA approval · 2009-10-16FDA Approved: RITUXAN — Supplemental Application (Genentech, Inc.)
FDA approved a supplemental application for Rituxan (rituximab) from Genentech.